|1.||Austin, Eric D: 4 articles (01/2015 - 08/2009)|
|2.||Loyd, James E: 3 articles (11/2012 - 06/2009)|
|3.||Phillips, John A: 3 articles (11/2012 - 06/2009)|
|4.||Leandro, João: 3 articles (01/2011 - 09/2008)|
|5.||Leandro, Paula: 3 articles (01/2011 - 09/2008)|
|6.||Zhu, Bangshang: 2 articles (05/2014 - 03/2014)|
|7.||Hemnes, Anna R: 2 articles (02/2014 - 11/2012)|
|8.||Douwes, Johannes M: 2 articles (11/2013 - 12/2011)|
|9.||Berger, Rolf M F: 2 articles (11/2013 - 12/2011)|
|10.||Roofthooft, Marcus T R: 2 articles (11/2013 - 12/2011)|
|1.||Connective Tissue Diseases (Connective Tissue Disease)
01/01/2015 - "The etiology of PAH was idiopathic or heritable PAH (I/HPAH) in 38 cases, PAH associated with connective tissue disease in 3, and Eissenmenger's syndrome in the remaining case. "
08/01/2014 - "To investigate survival, treatment escalation, effects of first-line single- and first-line combination therapy and prognostic markers in idiopathic- (IPAH), hereditary- (HPAH) and connective tissue disease-associated (CTD-PAH) pulmonary arterial hypertension (PAH). "
01/01/2013 - "The aim of this study was to determine whether the levels of endothelial and platelet-derived microparticles could vary between different forms of PAH: idiopathic PAH (iPAH), heritable PAH associated with BMPR2 (Bone morphogenetic protein receptor, type II) mutation (hPAH) and PAH associated with connective tissue diseases (aPAH). "
05/05/2014 - "Compared to the HPAH-DOX micelles and the physical mixture of HPAH-DOX and LY, the LY-loaded HPAH-DOX micelles induced a higher proliferation inhibition of tumor cells, illustrating a synergistic effect of LY and DOX. "
05/05/2014 - "The in vitro evaluation demonstrated that the LY-loaded HPAH-DOX micelles could rapidly enter cancer cells and then release LY and DOX in response to an intracellular acidic environment. "
03/01/2014 - "The results indicate that the nanoscale PEG-HPAH-DTX micelles may serve as a selective tumor-targeting drug delivery system."
03/01/2014 - "When combined with the administration of glucose, the PEG-HPAH-DTX micelles exhibited a superior anti-tumor efficacy and a lower systemic toxicity in vivo. "
03/01/2014 - "The docetaxel (DTX)-loaded PEG-HPAH micelles presented a high cytotoxic activity against tumor cells in vitro. "
01/01/2011 - "The missense mutation pG46S in the regulatory (R) domain of human phenylalanine hydroxylase (hPAH), associated with a severe form of phenylketonuria, generates a misfolded protein which is rapidly degraded on expression in HEK293 cells. "
09/01/2010 - "Phenylketonuria (PKU; OMIM 261600), the most common disorder of amino acid metabolism, is caused by a deficient activity of human phenylalanine hydroxylase (hPAH). "
09/01/2008 - "Phenylketonuria, the most frequent disorder of amino acid metabolism, is caused by a deficient activity of human phenylalanine hydroxylase (hPAH). "
10/01/1998 - "The molecular basis for the metabolic defect in patients with phenylketonuria has been characterized for seven missense point mutations (R252G/Q, L255V/S, A259V/T and R270S) and a termination mutation (G272X) in an evolutionarily conserved motif of exon 7 in the catalytic domain of the human phenylalanine hydroxylase (hPAH) gene. "
06/18/2002 - "Human phenylalanine hydroxylase (hPAH) is a tetrameric enzyme that catalyzes the hydroxylation of L-phenylalanine (L-Phe) to L-tyrosine; a dysfunction of this enzyme causes phenylketonuria. "
|4.||Heart Diseases (Heart Disease)
11/01/2013 - "A Dutch national cohort of 74 children with either idiopathic or heritable PAH (IPAH/HPAH, n = 43) or PAH associated with congenital heart disease (PAH-CHD, n = 31) were followed from 1993 to 2012. "
05/01/2013 - "Hemodynamic pulmonary arterial hypertension (HPAH) is a common symptom in congenital heart disease (CHD) patients with a left-to-right shunt. "
12/01/2011 - "To assess the occurrence and prognostic value of acute vasodilator response (AVR) in paediatric vs. adult pulmonary arterial hypertension, and idiopathic/hereditary pulmonary arterial hypertension (iPAH/HPAH) vs. pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD) using three different response criteria. "
06/30/2009 - "We review the finding of missense variants and variants of unknown significance in BMPR2 in IPAH/HPAH, fenfluramine exposure, and PAH associated with congenital heart disease. "
|5.||Genetic Predisposition to Disease (Genetic Predisposition)
10/01/2011 - "With advances in genomic technology and with international collaborative efforts, genome-wide association studies will be conducted to identify additional genes for HPAH, genetic modifiers for BMPR2 penetrance, and genetic susceptibility to IPAH. "
08/01/2011 - "The pathogenesis of HPAH and SSc has been linked to both a genetic predisposition and epigenetic factors. "
06/30/2009 - "With advances in genomic technology and with international collaborative efforts, genome-wide association studies will be conducted to identify additional genes for HPAH, genetic modifiers for BMPR2 penetrance and genetic susceptibility to IPAH. "
|2.||Type II Bone Morphogenetic Protein Receptors (Bone Morphogenetic Protein Receptor Type II)
|4.||Ethylene Glycol (Monoethylene Glycol)
|6.||Idiopathic pulmonary hypertension
|7.||Phenylalanine Hydroxylase (Phenylalanine 4 Monooxygenase)
|8.||Bone Morphogenetic Proteins (Bone Morphogenetic Protein)